S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Biden To Unleash "Choke Point" Operation On America? (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
Biden To Unleash "Choke Point" Operation On America? (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Biden To Unleash "Choke Point" Operation On America? (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Biden To Unleash "Choke Point" Operation On America? (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
Biden To Unleash "Choke Point" Operation On America? (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Biden To Unleash "Choke Point" Operation On America? (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Biden To Unleash "Choke Point" Operation On America? (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
Biden To Unleash "Choke Point" Operation On America? (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Biden To Unleash "Choke Point" Operation On America? (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Biden To Unleash "Choke Point" Operation On America? (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
Biden To Unleash "Choke Point" Operation On America? (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Biden To Unleash "Choke Point" Operation On America? (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
OTCMKTS:RGRX

RegeneRx Biopharmaceuticals - RGRX Stock Forecast, Price & News

$0.12
0.00 (0.00%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.12
$0.12
50-Day Range
$0.11
$0.15
52-Week Range
$0.10
$0.25
Volume
200 shs
Average Volume
9,083 shs
Market Capitalization
$17.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RGRX stock logo

About RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Stock

RegeneRx Biopharmaceuticals, Inc. engages in the development of a novel therapeutic peptide, Thymosin beta 4 for tissue and organ protection, repair, and regeneration. Its product pipeline includes RGN-259, RGN-352, and RGN-137. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.

Receive RGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RGRX Stock News Headlines

Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Clover Biopharmaceuticals Ltd (2197)
RegeneRx Issues 2022 Letter To Stockholders
RGRX Real-Time Quotes
RGRX After-Hours Quotes
See More Headlines
Receive RGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RGRX Company Calendar

Today
3/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:RGRX
Employees
3
Year Founded
N/A

Profitability

Net Income
$-1,600,000.00
Net Margins
-2,326.70%
Pretax Margin
-2,326.70%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($0.02) per share

Miscellaneous

Free Float
125,606,000
Market Cap
$17.17 million
Optionable
Not Optionable
Beta
0.56

Key Executives

  • Allan L. Goldstein
    Chairman & Chief Scientific Officer
  • J. J. Finkelstein
    President, Chief Executive Officer & Director













RGRX Stock - Frequently Asked Questions

How have RGRX shares performed in 2023?

RegeneRx Biopharmaceuticals' stock was trading at $0.1389 at the beginning of 2023. Since then, RGRX stock has decreased by 13.9% and is now trading at $0.1196.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of RegeneRx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RegeneRx Biopharmaceuticals investors own include Biocept (BIOC), Fulcrum Therapeutics (FULC), Inpixon (INPX), OPKO Health (OPK), VBI Vaccines (VBIV), Vaxart (VXRT), AVEO Pharmaceuticals (AVEO), Palatin Technologies (PTN), Sorrento Therapeutics (SRNE) and Sierra Oncology (SRRA).

What is RegeneRx Biopharmaceuticals' stock symbol?

RegeneRx Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "RGRX."

How do I buy shares of RegeneRx Biopharmaceuticals?

Shares of RGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RegeneRx Biopharmaceuticals' stock price today?

One share of RGRX stock can currently be purchased for approximately $0.12.

How much money does RegeneRx Biopharmaceuticals make?

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) has a market capitalization of $17.17 million and generates $80,000.00 in revenue each year.

How can I contact RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 470, ROCKVILLE MD, 20850. The official website for the company is www.regenerx.com. The biopharmaceutical company can be reached via phone at (301) 208-9191, via email at info@regenerx.com, or via fax at 301-280-1996.

This page (OTCMKTS:RGRX) was last updated on 3/26/2023 by MarketBeat.com Staff